Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corcept Therapeutics (CORT) Accumulated Expenses (2016 - 2025)

Historic Accumulated Expenses for Corcept Therapeutics (CORT) over the last 13 years, with Q3 2025 value amounting to $108.4 million.

  • Corcept Therapeutics' Accumulated Expenses rose 3647.31% to $108.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $108.4 million, marking a year-over-year increase of 3647.31%. This contributed to the annual value of $90.7 million for FY2024, which is 7567.99% up from last year.
  • As of Q3 2025, Corcept Therapeutics' Accumulated Expenses stood at $108.4 million, which was up 3647.31% from $91.1 million recorded in Q2 2025.
  • Corcept Therapeutics' 5-year Accumulated Expenses high stood at $108.4 million for Q3 2025, and its period low was $18.0 million during Q1 2021.
  • In the last 5 years, Corcept Therapeutics' Accumulated Expenses had a median value of $51.6 million in 2023 and averaged $52.6 million.
  • In the last 5 years, Corcept Therapeutics' Accumulated Expenses crashed by 812.15% in 2021 and then skyrocketed by 13675.03% in 2023.
  • Quarter analysis of 5 years shows Corcept Therapeutics' Accumulated Expenses stood at $27.7 million in 2021, then increased by 11.33% to $30.8 million in 2022, then soared by 67.63% to $51.6 million in 2023, then skyrocketed by 75.68% to $90.7 million in 2024, then rose by 19.57% to $108.4 million in 2025.
  • Its Accumulated Expenses stands at $108.4 million for Q3 2025, versus $91.1 million for Q2 2025 and $88.9 million for Q1 2025.